Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 4Dermatologic 4Breast 3Head & Neck 2Genitourinary 2Thoracic 1Plasma cell 1Lymphoid 1Gynecologic 1Gastrointestinal 1

Conditions

Neoplasms, Plasma Cell 3Urinary Bladder Neoplasms 1Smoldering Multiple Myeloma 1Sarcoma 1Ovarian Neoplasms 1Melanoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

selinexor 2pazopanib 2Radiotherapy 2Injections 2Ifosfamide 2Filgrastim 2Doxorubicin 2Cyclophosphamide 2sargramostim 1resiquimod 1repotrectinib 1poly ICLC 1interferon-alfa-1b 1cc-486 1aldesleukin 1Voriconazole 1Thalidomide 1Suspensions 1Rituximab 1Radiation 1Quality of Life 1Proton Therapy 1Peripheral Blood Stem Cell Transplantation 1Pentetic Acid 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Minocycline 1Methotrexate 1Melphalan 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × poly ICLC × Plasma cell × Clear all
NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡